Comparison of the efficacy among nilotinib, dasatinib, flumatinib and imatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients: A real-world multi-center retrospective study
There are limited data comprehensively comparing therapy responses and outcomes among nilotinib, dasatinib, flumatinib and imatinib for newly diagnosed chronic-phase chronic myeloid leukemia in a real-world setting. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 14, 2024 Category: Hematology Authors: Xiaoshuai Zhang, Na Xu, Yunfan Yang, Hai Lin, Bingcheng Liu, Xin Du, Xiaoli Liu, Rong Liang, Chunyan Chen, Jian Huang, Huanling Zhu, Ling Pan, Xiaodong Wang, Guohui Li, Zhuogang Liu, Yanqing Zhang, Zhenfang Liu, Jianda Hu, Chunshui Liu, Fei Li, Wei Yang, Source Type: research
Therapeutic drug monitoring of imatinib - how far are we in the leukemia setting?
Expert Rev Clin Pharmacol. 2024 Feb 12:1-10. doi: 10.1080/17512433.2024.2312256. Online ahead of print.ABSTRACTINTRODUCTION: Tyrosine kinase inhibitors (TKIs) have revolutionized survival rates of chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) and replaced hematopoietic stem cell transplantation (hSCT) as the key treatment option for these patients. More recently, the so-called Philadelphia chromosome-like (Ph-like) ALL has similarly benefitted from TKIs. However, many patients shift from the first generation TKI, imatinib, due to treatment-related toxicities or...
Source: Pharmacological Reviews - February 12, 2024 Category: Drugs & Pharmacology Authors: Anna Sofie Buhl Rasmussen Christen Lykkegaard Andersen Allan Weimann Tianwu Yang Camille Tron Virginie Gandemer Kim Dalhoff Cecilie Utke Rank Kjeld Schmiegelow Source Type: research
KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem
Expert Opin Investig Drugs. 2024 Feb 14:1-12. doi: 10.1080/13543784.2024.2318317. Online ahead of print.ABSTRACTINTRODUCTION: Approximately 90% of gastrointestinal stromal tumors (GISTs) are driven by activating mutations in receptor tyrosine-kinases KIT or PDGFRA. Despite the outstanding results of first-line imatinib in advanced GIST, resistance ultimately occurs mainly through secondary mutations in KIT/PDGFRA. Other tyrosine-kinase inhibitors (TKIs) with a broader spectrum of activity against these mutations are approved after imatinib failure. However, response rates and progression-free survival are drastically lower...
Source: Expert Opinion on Investigational Drugs - February 12, 2024 Category: Drugs & Pharmacology Authors: Carlo Mar ía Cicala Iv án Olivares-Rivas Jon Ander Aguirre-Carrillo C ésar Serrano Source Type: research
Therapeutic drug monitoring of imatinib - how far are we in the leukemia setting?
Expert Rev Clin Pharmacol. 2024 Feb 12:1-10. doi: 10.1080/17512433.2024.2312256. Online ahead of print.ABSTRACTINTRODUCTION: Tyrosine kinase inhibitors (TKIs) have revolutionized survival rates of chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) and replaced hematopoietic stem cell transplantation (hSCT) as the key treatment option for these patients. More recently, the so-called Philadelphia chromosome-like (Ph-like) ALL has similarly benefitted from TKIs. However, many patients shift from the first generation TKI, imatinib, due to treatment-related toxicities or...
Source: Expert Review of Clinical Pharmacology - February 12, 2024 Category: Drugs & Pharmacology Authors: Anna Sofie Buhl Rasmussen Christen Lykkegaard Andersen Allan Weimann Tianwu Yang Camille Tron Virginie Gandemer Kim Dalhoff Cecilie Utke Rank Kjeld Schmiegelow Source Type: research
Effects of pulsed electrical stimulation on α-smooth muscle actin and type I collagen expression in human dermal fibroblasts
In this study, we investigated PES effects on fibroblast collagen production and differentiation into myofibroblasts. HFs were electrically stimulated at 4,800 Hz and 5 V for 60 min. Imatinib, a specific inhibitor of PDGF receptors, was treated before PES. Six hours after PES, PDGFA, α-smooth muscle actin (α-SMA) and collagen type I α1 chain gene expressions were upregulated in PES group. Imatinib suppressed the promoted expression except for PDGFA. Immunofluorescence staining and ELISA showed the production of α-SMA and collagen I was enhanced in PES group but suppressed in PES + imatinib group at 48 h after PES. Ther...
Source: Bioscience, Biotechnology, and Biochemistry - February 10, 2024 Category: Biochemistry Authors: Hiroya Urabe Ryuji Akimoto Shohei Kamiya Katsu Hosoki Hideyuki Ichikawa Toshio Nishiyama Source Type: research
Effects of pulsed electrical stimulation on α-smooth muscle actin and type I collagen expression in human dermal fibroblasts
In this study, we investigated PES effects on fibroblast collagen production and differentiation into myofibroblasts. HFs were electrically stimulated at 4,800 Hz and 5 V for 60 min. Imatinib, a specific inhibitor of PDGF receptors, was treated before PES. Six hours after PES, PDGFA, α-smooth muscle actin (α-SMA) and collagen type I α1 chain gene expressions were upregulated in PES group. Imatinib suppressed the promoted expression except for PDGFA. Immunofluorescence staining and ELISA showed the production of α-SMA and collagen I was enhanced in PES group but suppressed in PES + imatinib group at 48 h after PES. Ther...
Source: Bioscience, Biotechnology, and Biochemistry - February 10, 2024 Category: Biochemistry Authors: Hiroya Urabe Ryuji Akimoto Shohei Kamiya Katsu Hosoki Hideyuki Ichikawa Toshio Nishiyama Source Type: research
The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB/STAT5 signalling pathways and sensitivity to TKI in ph-like ALL
J Cell Mol Med. 2024 Feb;28(3):e18114. doi: 10.1111/jcmm.18114.ABSTRACTPatients with Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like ALL) often face a grim prognosis, with PDGFRB gene fusions being commonly detected in this subgroup. Our study has unveiled a newfound fusion gene, TERF2::PDGFRB, and we have found that patients carrying this fusion gene exhibit sensitivity to dasatinib. Ba/F3 cells harbouring the TERF2::PDGFRB fusion display IL-3-independent cell proliferation through activation of the p-PDGFRB and p-STAT5 signalling pathways. These cells exhibit reduced apoptosis and demonstrate sensitiv...
Source: J Cell Mol Med - February 7, 2024 Category: Molecular Biology Authors: Guo-Fa Xu Zhao Zeng Zhi-Bo Zhang Xiao-Mei Zhang Man Wang Qing Xiao Jun Li Xiao-Qing Xie Sanxiu He Hui-Hui Fu Yi Liu Zai-Liang Yang Yu Chen Jie Shi Biao Wang Hui-Ying Qiu Qi Zhou Yao Liu Su-Ning Chen Source Type: research
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape
AbstractChronic myeloid leukemia is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome and the consequent BCR::ABL1 oncoprotein. In the era before the introduction of tyrosine kinase inhibitors (TKIs), the only potentially curative treatment was allogeneic hematopoietic stem cell transplantation (HSCT). Here, we present the case of a patient affected by CML who experienced a relapse 20 years after allogeneic HSCT. Following relapse, the patient was treated with imatinib and bosutinib, resulting in a deep molecular response and successfully discontinued treatment. Additional analysi...
Source: Annals of Hematology - February 7, 2024 Category: Hematology Source Type: research
Efficient cocrystal coformer screening based on a Machine learning Strategy: A case study for the preparation of imatinib cocrystal with enhanced physicochemical properties
Eur J Pharm Biopharm. 2024 Feb 1:114201. doi: 10.1016/j.ejpb.2024.114201. Online ahead of print.ABSTRACTCocrystal engineering, which involves the self-assembly of two or more components into a solid-state supramolecular structure through non-covalent interactions, has emerged as a promising approach to tailor the physicochemical properties of active pharmaceutical ingredient (API). Efficient coformer screening for cocrystal remains a challenge. Herein, a prediction strategy based on machine learning algorithms was employed to predict cocrystal formation and seven reliable models with accuracy over 0.890 were successfully c...
Source: European Journal of Pharmaceutics and Biopharmaceutics - February 3, 2024 Category: Drugs & Pharmacology Authors: Xiaoxiao Liang Shiyuan Liu Zebin Li Yuehua Deng Yanbin Jiang Huaiyu Yang Source Type: research
A pilot phase 2 study of ruxolitinib for the treatment of steroid-refractory hypereosinophilic syndrome
Although the approvals of mepolizumab and imatinib for treatment of hypereosinophilic syndrome (HES) have improved outcomes, responses vary and options for steroid-refractory, PDGFR-negative disease remain limited. Case reports suggest that JAK inhibitors may be effective in JAK2-associated myeloid HES and in steroid-resistant lymphocytic variant HES (LHES). (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Charles Anderson, Paneez Khoury, Michelle Makiya, Xiaoping Sun, Irina Maric, Amy Klion Source Type: research
Unexpected reaction of “wild-type” gastrointestinal stromal tumor to imatinib: case report and literature review
ConclusionThis unexpected response suggests that wild-type GISTs may benefit from TKIs treatment, and the potential mechanisms warrant further investigation. Additionally, true wild-type GIST may not be discerned due to current limitations of Next-Generation Sequencing(NGS). Therefore, for advanced/high-risk GIST, additional genetic analysis can be performed after negative NGS results. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - January 31, 2024 Category: Cancer & Oncology Source Type: research
Immortalised chronic myeloid leukemia (CML) derived mesenchymal stromal cells (MSCs) line retains the immunomodulatory and chemoprotective properties of CML patient-derived MSCs
Cell Signal. 2024 Jan 27;116:111067. doi: 10.1016/j.cellsig.2024.111067. Online ahead of print.ABSTRACTDespite the success of Tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML), leukemic stem cells (LSCs) persist, contributing to relapse and resistance. CML Mesenchymal Stromal Cells (MSCs) help in LSC maintenance and protection from TKIs. However, the limited passage and self-differentiation abilities of primary CML MSCs hinder extensive research. To overcome this, we generated and characterized an immortalised CML patient-derived MSC (iCML MSC) line and assessed its role in LSC maintenance. We al...
Source: Cellular Signalling - January 28, 2024 Category: Cytology Authors: Esther Sathya Bama Benjamin Elizabeth Vinod Raveen Stephen Stallon Illangeswaran Bharathi M Rajamani Rakhi Thalayattu Vidhyadharan Abhirup Bagchi Arnab Maity Ajith Mohan Ganesh Parasuraman Soosai Manickam Amirtham Aby Abraham Shaji R Velayudhan Poonkuzhal Source Type: research
Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia
CONCLUSION: Imatinib could result in a decline in eGFR which was clinically similar to early-stage CKD patients. We did not observe significant kidney function deterioration in patients receiving 2GTKIs including dasatinib and nilotinib. We recommend close renal function monitoring in patients receiving imatinib, especially for elderly patients with lower baseline eGFR and hypertension.PMID:38281820 | DOI:10.1016/j.clml.2023.12.004 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 28, 2024 Category: Cancer & Oncology Authors: Özge Sönmez Nurg ül Özgür Yurttaş İlker İhtiyaroğlu Halil Mete Çakır Zeynep Atl ı Tu ğrul Elverdi Ay şe Salihoğlu Nurhan Seyahi Muhlis Cem Ar Şeniz Öngören Zafer Ba şlar Teoman Soysal Ahmet Emre E şkazan Source Type: research
The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia
This article offers a comprehensive analysis of the structural attributes of BCR-ABL, emphasizing its pivotal role as a biomarker and therapeutic target in CML. It underscores the imperative for ongoing research to refine treatment modalities and enhance overall outcomes in managing CML.PMID:38280275 | DOI:10.1016/j.prp.2024.155161 (Source: Pathology, Research and Practice)
Source: Pathology, Research and Practice - January 27, 2024 Category: Pathology Authors: Mohamed El-Tanani Hamdi Nsairat Ismail I Matalka Yin Fai Lee Manfredi Rizzo Alaa A Aljabali Vijay Mishra Yachana Mishra Altijana Hromi ć-Jahjefendić Murtaza M Tambuwala Source Type: research
Efficiency and Toxicity of Imatinib Mesylate combined with Atorvastatin Calcium in the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease: A Single-center, Prospective, Single-arm, Open-label study
CONCLUSION: Combination treatment with imatinib mesylate and atorvastatin calcium was effective in treating SR-cGVHD and significantly decreased target organ injury, especially liver damage, indicating that T-cell regulatory function may play an important role in this process.PMID:38232716 | DOI:10.1159/000536174 (Source: Acta Haematologica)
Source: Acta Haematologica - January 17, 2024 Category: Hematology Authors: Ting Chen JiaLi Li Xiao Wei Han Yao LiDan Zhu Jia Liu YuQing Liu Ping Wang YiMei Feng ShiChun Gao HuanFeng Liu Lu Wang Lu Zhao Li Gao Cheng Zhang Lei Gao Xi Zhang PeiYan Kong Source Type: research
